Cardiac Science Corporation is a global leader in cardiac monitoring and defibrillation products and services. It has 550 employees worldwide and operates in North America, Europe, and Asia. The company manufactures AEDs that have been deployed in over 300,000 locations globally and have helped save over 100 lives in some public access defibrillation programs. AEDs can significantly increase survival rates for sudden cardiac arrest when used within 10 minutes of the event.
MIRCaM provides real time analysis and generate instant alarms on episode detection, thus enhancing patient care and safety. It gives new possibilities for monitoring of vital parameters with wearable biomedical sensors, and will give the patient the freedom to be mobile and still be under continuous monitoring and thereby offer better quality of patient care.
MIRCaM is intended for detecting cardiac arrhythmias, myocardial ischemia and Infarctions and it can also be used to follow up critical patients from their home while they are carrying out daily activities. MIRCaM has the ability to detect a number of heart problems that do not show up during standard electrocardiography tests or during a stress test. Because it involves continuous monitoring, it is also particularly useful in detecting conditions that occur sporadically, such as during sleep or at times of emotional or physical stress.
This document discusses a fitness tracker solution called Cardiolyse that analyzes electrocardiogram (ECG) data recorded by fitness trackers. Cardiolyse has developed a cloud-based ECG processing platform that uses algorithms to define over 100 parameters from a recorded ECG that provide information about heart health. This includes providing an overall heart health score, measures of stamina, emotional state, heart muscle state, and heart rate disturbances. The platform also forecasts cardiovascular disease risk. Partners can integrate Cardiolyse's API to add these ECG analysis capabilities to their products. Cardiolyse has validated the accuracy of its algorithms through large-scale medical screenings and research collaborations.
Advanced Cardiac Emergency Hospital in KolkataRonit Roy
ILS Hospitals is one of the advanced cardiac emergency hospital in Kolkata, offering cardiac ailments to adults and children. Rush into ILS during cardiac emergency.
Cervical Arterial Dysfunction & Clinical Practice: Moving ForwardAlan J Taylor
A short description of current concepts in the understanding of vascular risk in the cervical spine, with specific reference to cervical arterial dysfunction (CAD). This presentation gives an overview of this 'umbrella term' and relates to the pathologies that fall under it.
Cardium Therapeutics' (NYSE MKT: CXM) Generx® product candidate (alferminogene tadenovec, Ad5FGF-4) is a DNA-based angiogenic growth factor therapeutic being developed for the potential treatment of patients with advanced coronary artery disease. Generx is designed to stimulate the growth of supplemental collateral blood vessels in the heart in order to enhance myocardial blood flow in patients who have insufficient blood flow due to atherosclerotic plaque restricting flow in the coronary arteries that supply the heart. Generx has progressed through four randomized, placebo-controlled clinical studies at over 100 medical centers in the United States and Western Europe that have enrolled over 650 patients.
Generx is designed as a disease-modifying regenerative medicine therapeutic that can elicit structural and physiologic changes in the heart (the growth of new collateral blood vessels) following a one-time intracoronary administration from a standard cardiac infusion catheter. In contrast, traditional drug therapies such as nitrates and beta blockers provide transient symptomatic relief of anginal chest pain without changing the underlying disease. In the United States, anti-anginal drugs have traditionally been registered by the FDA based on improvements in exercise treadmill tolerance testing (ETT), which can confirm short-term symptomatic relief of angina. Based on the disease-modifying nature of Generx, Cardium believes that a more objective and appropriate measure to assess the effectiveness of angiogenic therapy is cardiac perfusion, the actual blood flow in the heart under stress using SPECT imaging (single photon emission computed tomography) or another advanced imaging technique. Cardiac perfusion directly shows and quantifies improvements in the underlying physiologic condition, i.e. insufficient blood flow under stress. Generx is currently being developed for international markets outside United States as a treatment alternative for patients who may not have access to or may not be candidates for costly and invasive surgical revascularization procedures, such as coronary artery bypass surgery and angioplasty/stents.
Learn more at: http://cardiumthx.com/generx.html
- Cardiac Science is a company founded in 1991 that develops automated external defibrillator (AED) technology, with over 500,000 AEDs deployed globally.
- The document discusses Cardiac Science's history of innovation, including developing the first fully automatic bedside defibrillator and receiving FDA clearance for the first AED.
- It promotes the Powerheart G5 AED as the first FDA-cleared AED to combine features like fully automatic shock delivery, dual-language functionality, and variable escalating energy.
1. The document discusses the benefits of implementing an automated external defibrillator (AED) program at workplaces to respond to sudden cardiac arrest emergencies.
2. It highlights that survival rates for sudden cardiac arrest victims can be as high as 86% if an AED shock is delivered within 1 minute, compared to only a 5% survival rate if relying solely on emergency medical services.
3. The document promotes Cardiac Science as a provider of AED devices and programs, noting their reliability, ease of use, long warranty, and ability to deliver standardized global programs.
MIRCaM provides real time analysis and generate instant alarms on episode detection, thus enhancing patient care and safety. It gives new possibilities for monitoring of vital parameters with wearable biomedical sensors, and will give the patient the freedom to be mobile and still be under continuous monitoring and thereby offer better quality of patient care.
MIRCaM is intended for detecting cardiac arrhythmias, myocardial ischemia and Infarctions and it can also be used to follow up critical patients from their home while they are carrying out daily activities. MIRCaM has the ability to detect a number of heart problems that do not show up during standard electrocardiography tests or during a stress test. Because it involves continuous monitoring, it is also particularly useful in detecting conditions that occur sporadically, such as during sleep or at times of emotional or physical stress.
This document discusses a fitness tracker solution called Cardiolyse that analyzes electrocardiogram (ECG) data recorded by fitness trackers. Cardiolyse has developed a cloud-based ECG processing platform that uses algorithms to define over 100 parameters from a recorded ECG that provide information about heart health. This includes providing an overall heart health score, measures of stamina, emotional state, heart muscle state, and heart rate disturbances. The platform also forecasts cardiovascular disease risk. Partners can integrate Cardiolyse's API to add these ECG analysis capabilities to their products. Cardiolyse has validated the accuracy of its algorithms through large-scale medical screenings and research collaborations.
Advanced Cardiac Emergency Hospital in KolkataRonit Roy
ILS Hospitals is one of the advanced cardiac emergency hospital in Kolkata, offering cardiac ailments to adults and children. Rush into ILS during cardiac emergency.
Cervical Arterial Dysfunction & Clinical Practice: Moving ForwardAlan J Taylor
A short description of current concepts in the understanding of vascular risk in the cervical spine, with specific reference to cervical arterial dysfunction (CAD). This presentation gives an overview of this 'umbrella term' and relates to the pathologies that fall under it.
Cardium Therapeutics' (NYSE MKT: CXM) Generx® product candidate (alferminogene tadenovec, Ad5FGF-4) is a DNA-based angiogenic growth factor therapeutic being developed for the potential treatment of patients with advanced coronary artery disease. Generx is designed to stimulate the growth of supplemental collateral blood vessels in the heart in order to enhance myocardial blood flow in patients who have insufficient blood flow due to atherosclerotic plaque restricting flow in the coronary arteries that supply the heart. Generx has progressed through four randomized, placebo-controlled clinical studies at over 100 medical centers in the United States and Western Europe that have enrolled over 650 patients.
Generx is designed as a disease-modifying regenerative medicine therapeutic that can elicit structural and physiologic changes in the heart (the growth of new collateral blood vessels) following a one-time intracoronary administration from a standard cardiac infusion catheter. In contrast, traditional drug therapies such as nitrates and beta blockers provide transient symptomatic relief of anginal chest pain without changing the underlying disease. In the United States, anti-anginal drugs have traditionally been registered by the FDA based on improvements in exercise treadmill tolerance testing (ETT), which can confirm short-term symptomatic relief of angina. Based on the disease-modifying nature of Generx, Cardium believes that a more objective and appropriate measure to assess the effectiveness of angiogenic therapy is cardiac perfusion, the actual blood flow in the heart under stress using SPECT imaging (single photon emission computed tomography) or another advanced imaging technique. Cardiac perfusion directly shows and quantifies improvements in the underlying physiologic condition, i.e. insufficient blood flow under stress. Generx is currently being developed for international markets outside United States as a treatment alternative for patients who may not have access to or may not be candidates for costly and invasive surgical revascularization procedures, such as coronary artery bypass surgery and angioplasty/stents.
Learn more at: http://cardiumthx.com/generx.html
- Cardiac Science is a company founded in 1991 that develops automated external defibrillator (AED) technology, with over 500,000 AEDs deployed globally.
- The document discusses Cardiac Science's history of innovation, including developing the first fully automatic bedside defibrillator and receiving FDA clearance for the first AED.
- It promotes the Powerheart G5 AED as the first FDA-cleared AED to combine features like fully automatic shock delivery, dual-language functionality, and variable escalating energy.
1. The document discusses the benefits of implementing an automated external defibrillator (AED) program at workplaces to respond to sudden cardiac arrest emergencies.
2. It highlights that survival rates for sudden cardiac arrest victims can be as high as 86% if an AED shock is delivered within 1 minute, compared to only a 5% survival rate if relying solely on emergency medical services.
3. The document promotes Cardiac Science as a provider of AED devices and programs, noting their reliability, ease of use, long warranty, and ability to deliver standardized global programs.
The document summarizes the HeartSine samaritan PAD 500P public access defibrillator. It has a CPR Advisor feature that uses impedance cardiography to assess CPR effectiveness and provide visual and audio feedback to guide rescuers. It is compact and durable with high dust/moisture protection. The device utilizes proprietary electrode technology and waveform to assess rhythm and recommend defibrillation if needed. It has a long battery life and combined electrode/battery cartridge with a 4-year shelf life to reduce maintenance costs.
The document outlines a management presentation for a company that provides external counter pulsation (ECP) therapy for cardiovascular disease. ECP is a non-invasive treatment that uses pressure cuffs on the legs to improve blood flow. The presentation discusses the company's ECP device, clinical evidence demonstrating ECP's benefits, reimbursement for ECP, and how ECP can provide a new income stream for physicians while reducing healthcare costs compared to surgical interventions.
The document is a catalog for workplace safety training and preparedness programs from the American Red Cross. It provides an overview of the various programs offered, including: OSHA compliant first aid/CPR/AED training, corporate preparedness programs, a comprehensive AED program, safety and preparedness products, mobile apps, corporate wellness offerings, and instructor courses. Partnering with the Red Cross provides benefits such as flexibility, nationwide availability, evidence-based science, and being a one-stop shop for all safety and preparedness needs.
The document describes a stress monitoring and management system called Stress Combat that uses wearable devices like a smart wristband and shirt to monitor heart rate and stress levels, provides recommendations for reducing stress, and offers access to doctors for advice through a mobile app. Stress Combat aims to help individuals, businesses, and society by improving health, productivity, and reducing healthcare costs through effective stress management.
This document is a price list from Specialised Industry Consultants that provides prices and information on various first aid and safety equipment, including defibrillators, first aid kits, electrical safety equipment, and workplace training. It lists prices and features of different defibrillator models starting from $1,824.83 for a basic workplace first aid kit to $3,990 for an advanced defibrillator model with ECG capabilities. Additional information is provided on defibrillator insurance and an AED selection guide comparing defibrillator models and their uses.
HEARTSafe Communities exist in many areas of the US and abroad. HEARTSafe helps communities save lives by improving response and care for cardiac arrest victims.
The document provides information about a proposed self-powering pacemaker that aims to cure bradycardia by healing the natural pacemaker. It discusses: the team developing the product; the large market opportunity given the growing elderly population; the unique characteristics of the proposed pacemaker including being leadless, self-powering, and able to heal the natural pacemaker; the regulatory approval process through IDE and PMA trials; and a three phase plan to target the US, European, and Asia-Pacific markets.
This document discusses launching a medical device and provides an overview of the FDA approval process. It covers the Medical Device Amendments of 1976 that established three regulatory device classes. It also discusses the 510(k) and Premarket Approval (PMA) processes, including required clinical trials for PMA. Relevant anatomy, cardiac devices like pacemakers and ICDs, and regulatory standards are reviewed.
LEARN MORE ABOUT INVESTOR OPPORTUNITIES HERE: https://vivaquant.sppx.io/
We all know someone who has had a heart attack or other cardiac condition. And despite significant therapeutic and diagnostics advancements, heart disease and cardiac events remain the leading causes of death in both men and women in the United States and cost more than $200 billion in health care services annually. Earlier and more accurate arrhythmia diagnosis can help change that, but we need your help!
This document summarizes information about sudden cardiac arrest and the use of automated external defibrillators (AEDs) to treat it. It discusses that sudden cardiac arrest is a leading cause of death and discusses ventricular fibrillation as a cause. It then summarizes different AED models from Philips, Zoll, Medtronic, Physio-Control and Cardiac Science and how they provide features like real-time CPR feedback and quick shock capability.
Can college campuses act as springboards for the advancement of chain of surv...David Hiltz
Review current evidence based guidelines and recommendations.
Describe how a population and criteria based incentive program has been used to advance chain of survival priorities on college campuses.
Discuss the role of college based EMS agencies in advancing lifesaving priorities.
Explore the possibilities of widespread CPR education on college campuses using CPR Anytime.
Ventripoint has become an industry leader in the application of AI (artificial intelligence) to echocardiography. Ventripoint's VMS products are powered by its proprietary KBR technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI. This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all of Ventripoint's products that guide the company's future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the United States, Europe and Canada.
Peripheral Artery Disease (PAD) affects 8-12 million Americans and puts many at high risk of limb loss or death from heart attack or stroke. Biomedix has developed the PADnet 4.0 Vascular Assessment System to aid in early detection of PAD to improve outcomes. They are also launching a new PARTNERS Program that provides incentives for industry partners who refer customers to use the PADnet system, helping in Biomedix's mission to save limbs and lives.
Cytori Therapeutics is a leader in cell therapy with 57 issued patents and 75 pending. Their Celution device is approved in the EU for tissue ischemia and wounds. The company is conducting a US trial called ATHENA to assess the safety and feasibility of using adipose-derived regenerative cells to treat refractory heart failure. Cytori is also partnering with BARDA to develop their next generation Celution system and conduct proof-of-concept studies for burn treatments. Cytori aims to accelerate revenue growth and achieve profitability through expanding commercial sales and translational medicine programs.
Hic13 c parker continuna dcap abstract don walker award winnerJanna Guinen
Presentation abstract on the Disaster Cardiovascular Prevention Network, an interoperable remote cardiovascular monitoring program launched for evacuees following the Great Japan Earthquake of 2011.
Modern Approaches to Heart Disease Detection - Carl H. Rosner, CardioMag Imag...marcus evans Network
Carl H. Rosner, CardioMag Imaging, Inc. - Speaker at the marcus evans Medical Device Manufacturing Summit Fall 2012, delivered his presentation entitled Modern Approaches to Heart Disease Detection
An Overview of PERS Based Domestic Cardio-Pulmonary Resuscitation MachineIRJET Journal
The document discusses the development of a prototype for a Personal Emergency Response System (PERS) based domestic Cardio-Pulmonary Resuscitation (CPR) machine. The proposed CPR machine aims to provide temporary relief to cardiac patients by automatically compressing the chest at 100-105 compressions per minute to a depth of 5 inches, restoring normal blood circulation and breathing. It intends to be affordable, portable, battery-powered and easy to use without any specialized training. The document outlines the objectives, methodology, hardware requirements and future scope of the proposed low-cost domestic CPR machine.
LIFEPAK defibrillators can help save lives from sudden cardiac arrest, which can happen anytime and anywhere to anyone. The document discusses how early defibrillation within 3 minutes of collapse can increase survival rates to over 70%. It promotes placing automated external defibrillators in public spaces like workplaces, schools, and community centers to create more "Heart Safe Environments" and allow untrained bystanders to help save lives until emergency services arrive.
A study found that over 80% of patients referred to cardiac rehabilitation attended sessions in the year following hospitalization for coronary artery disease. Cardiac rehabilitation addresses risk factors like hypertension, obesity, and smoking, and reduces illness and death by about 25% compared to usual care. The Center for Cardiovascular Health at South Nassau Communities Hospital provides cardiac rehabilitation through a 12-week program including exercise, risk assessment, nutrition counseling, and education to help patients achieve the best possible recovery. The center treats patients with advanced technologies and clinical best practices.
The document summarizes the HeartSine samaritan PAD 500P public access defibrillator. It has a CPR Advisor feature that uses impedance cardiography to assess CPR effectiveness and provide visual and audio feedback to guide rescuers. It is compact and durable with high dust/moisture protection. The device utilizes proprietary electrode technology and waveform to assess rhythm and recommend defibrillation if needed. It has a long battery life and combined electrode/battery cartridge with a 4-year shelf life to reduce maintenance costs.
The document outlines a management presentation for a company that provides external counter pulsation (ECP) therapy for cardiovascular disease. ECP is a non-invasive treatment that uses pressure cuffs on the legs to improve blood flow. The presentation discusses the company's ECP device, clinical evidence demonstrating ECP's benefits, reimbursement for ECP, and how ECP can provide a new income stream for physicians while reducing healthcare costs compared to surgical interventions.
The document is a catalog for workplace safety training and preparedness programs from the American Red Cross. It provides an overview of the various programs offered, including: OSHA compliant first aid/CPR/AED training, corporate preparedness programs, a comprehensive AED program, safety and preparedness products, mobile apps, corporate wellness offerings, and instructor courses. Partnering with the Red Cross provides benefits such as flexibility, nationwide availability, evidence-based science, and being a one-stop shop for all safety and preparedness needs.
The document describes a stress monitoring and management system called Stress Combat that uses wearable devices like a smart wristband and shirt to monitor heart rate and stress levels, provides recommendations for reducing stress, and offers access to doctors for advice through a mobile app. Stress Combat aims to help individuals, businesses, and society by improving health, productivity, and reducing healthcare costs through effective stress management.
This document is a price list from Specialised Industry Consultants that provides prices and information on various first aid and safety equipment, including defibrillators, first aid kits, electrical safety equipment, and workplace training. It lists prices and features of different defibrillator models starting from $1,824.83 for a basic workplace first aid kit to $3,990 for an advanced defibrillator model with ECG capabilities. Additional information is provided on defibrillator insurance and an AED selection guide comparing defibrillator models and their uses.
HEARTSafe Communities exist in many areas of the US and abroad. HEARTSafe helps communities save lives by improving response and care for cardiac arrest victims.
The document provides information about a proposed self-powering pacemaker that aims to cure bradycardia by healing the natural pacemaker. It discusses: the team developing the product; the large market opportunity given the growing elderly population; the unique characteristics of the proposed pacemaker including being leadless, self-powering, and able to heal the natural pacemaker; the regulatory approval process through IDE and PMA trials; and a three phase plan to target the US, European, and Asia-Pacific markets.
This document discusses launching a medical device and provides an overview of the FDA approval process. It covers the Medical Device Amendments of 1976 that established three regulatory device classes. It also discusses the 510(k) and Premarket Approval (PMA) processes, including required clinical trials for PMA. Relevant anatomy, cardiac devices like pacemakers and ICDs, and regulatory standards are reviewed.
LEARN MORE ABOUT INVESTOR OPPORTUNITIES HERE: https://vivaquant.sppx.io/
We all know someone who has had a heart attack or other cardiac condition. And despite significant therapeutic and diagnostics advancements, heart disease and cardiac events remain the leading causes of death in both men and women in the United States and cost more than $200 billion in health care services annually. Earlier and more accurate arrhythmia diagnosis can help change that, but we need your help!
This document summarizes information about sudden cardiac arrest and the use of automated external defibrillators (AEDs) to treat it. It discusses that sudden cardiac arrest is a leading cause of death and discusses ventricular fibrillation as a cause. It then summarizes different AED models from Philips, Zoll, Medtronic, Physio-Control and Cardiac Science and how they provide features like real-time CPR feedback and quick shock capability.
Can college campuses act as springboards for the advancement of chain of surv...David Hiltz
Review current evidence based guidelines and recommendations.
Describe how a population and criteria based incentive program has been used to advance chain of survival priorities on college campuses.
Discuss the role of college based EMS agencies in advancing lifesaving priorities.
Explore the possibilities of widespread CPR education on college campuses using CPR Anytime.
Ventripoint has become an industry leader in the application of AI (artificial intelligence) to echocardiography. Ventripoint's VMS products are powered by its proprietary KBR technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI. This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all of Ventripoint's products that guide the company's future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the United States, Europe and Canada.
Peripheral Artery Disease (PAD) affects 8-12 million Americans and puts many at high risk of limb loss or death from heart attack or stroke. Biomedix has developed the PADnet 4.0 Vascular Assessment System to aid in early detection of PAD to improve outcomes. They are also launching a new PARTNERS Program that provides incentives for industry partners who refer customers to use the PADnet system, helping in Biomedix's mission to save limbs and lives.
Cytori Therapeutics is a leader in cell therapy with 57 issued patents and 75 pending. Their Celution device is approved in the EU for tissue ischemia and wounds. The company is conducting a US trial called ATHENA to assess the safety and feasibility of using adipose-derived regenerative cells to treat refractory heart failure. Cytori is also partnering with BARDA to develop their next generation Celution system and conduct proof-of-concept studies for burn treatments. Cytori aims to accelerate revenue growth and achieve profitability through expanding commercial sales and translational medicine programs.
Hic13 c parker continuna dcap abstract don walker award winnerJanna Guinen
Presentation abstract on the Disaster Cardiovascular Prevention Network, an interoperable remote cardiovascular monitoring program launched for evacuees following the Great Japan Earthquake of 2011.
Modern Approaches to Heart Disease Detection - Carl H. Rosner, CardioMag Imag...marcus evans Network
Carl H. Rosner, CardioMag Imaging, Inc. - Speaker at the marcus evans Medical Device Manufacturing Summit Fall 2012, delivered his presentation entitled Modern Approaches to Heart Disease Detection
An Overview of PERS Based Domestic Cardio-Pulmonary Resuscitation MachineIRJET Journal
The document discusses the development of a prototype for a Personal Emergency Response System (PERS) based domestic Cardio-Pulmonary Resuscitation (CPR) machine. The proposed CPR machine aims to provide temporary relief to cardiac patients by automatically compressing the chest at 100-105 compressions per minute to a depth of 5 inches, restoring normal blood circulation and breathing. It intends to be affordable, portable, battery-powered and easy to use without any specialized training. The document outlines the objectives, methodology, hardware requirements and future scope of the proposed low-cost domestic CPR machine.
LIFEPAK defibrillators can help save lives from sudden cardiac arrest, which can happen anytime and anywhere to anyone. The document discusses how early defibrillation within 3 minutes of collapse can increase survival rates to over 70%. It promotes placing automated external defibrillators in public spaces like workplaces, schools, and community centers to create more "Heart Safe Environments" and allow untrained bystanders to help save lives until emergency services arrive.
A study found that over 80% of patients referred to cardiac rehabilitation attended sessions in the year following hospitalization for coronary artery disease. Cardiac rehabilitation addresses risk factors like hypertension, obesity, and smoking, and reduces illness and death by about 25% compared to usual care. The Center for Cardiovascular Health at South Nassau Communities Hospital provides cardiac rehabilitation through a 12-week program including exercise, risk assessment, nutrition counseling, and education to help patients achieve the best possible recovery. The center treats patients with advanced technologies and clinical best practices.
5. Where you’ll find us CARDIAC SCIENCE | 350 units, saved 100 lives UK public access defibrillation program, saved 90 lives Over 800 units deployed worldwide All 222 locations worldwide, saved an employee 15 minutes after AED and CPR training was complete
8. 10% decrease in survival for every minute of delay* CARDIAC SCIENCE | * American Heart Association, Chapter 4: Defibrillation. In: Cummins RO, ed. Textbook of Advanced Cardiac Life Support. Dallas, TX: American Heart Association; 1994:1-2. Time is the Critical Factor
9. APPROXIMATE WHEN CARDIAC ARREST OCCURS SURVIVAL RATE Where AEDs Are NOT Present Outside of the hospital 5%* Where AEDs Are Present In a casino 74% † In an airplane/airport 40%-60% †† In the workplace 58% ††† CARDIAC SCIENCE | *Gillum RF. Sudden coronary death in the United States: 1980-1985. Circulation. 1989;79:756-765. † American Heart Association and Emergency Cardiac Care 2000 Guidelines, JAMA †† Chicago Department of Aviation, 2002 ††† Cardiac Science, Inc. Internal Data AEDs Save Lives
Let’s discuss the vision, and the third thing you need to have the best story: 3. You have to incorporate all the strengths of the company for it to be most compelling, and promote the vision of the company To rebrand ourselves as “The company people think of first” - If we DIDN’T do this, and we asked customers “What company do YOU think of first” for cardiology products and services, who would they reply? GE? Philips? Burdick? Quinton? Almost certainly not Cardiac Science. We know this. Now ask yourself – who do you represent? Who are we?
Let’s discuss the vision, and the third thing you need to have the best story: 3. You have to incorporate all the strengths of the company for it to be most compelling, and promote the vision of the company To rebrand ourselves as “The company people think of first” - If we DIDN’T do this, and we asked customers “What company do YOU think of first” for cardiology products and services, who would they reply? GE? Philips? Burdick? Quinton? Almost certainly not Cardiac Science. We know this. Now ask yourself – who do you represent? Who are we?
Let’s discuss the vision, and the third thing you need to have the best story: 3. You have to incorporate all the strengths of the company for it to be most compelling, and promote the vision of the company To rebrand ourselves as “The company people think of first” - If we DIDN’T do this, and we asked customers “What company do YOU think of first” for cardiology products and services, who would they reply? GE? Philips? Burdick? Quinton? Almost certainly not Cardiac Science. We know this. Now ask yourself – who do you represent? Who are we?
Let’s discuss the vision, and the third thing you need to have the best story: 3. You have to incorporate all the strengths of the company for it to be most compelling, and promote the vision of the company To rebrand ourselves as “The company people think of first” - If we DIDN’T do this, and we asked customers “What company do YOU think of first” for cardiology products and services, who would they reply? GE? Philips? Burdick? Quinton? Almost certainly not Cardiac Science. We know this. Now ask yourself – who do you represent? Who are we?
Let’s discuss the vision, and the third thing you need to have the best story: 3. You have to incorporate all the strengths of the company for it to be most compelling, and promote the vision of the company To rebrand ourselves as “The company people think of first” - If we DIDN’T do this, and we asked customers “What company do YOU think of first” for cardiology products and services, who would they reply? GE? Philips? Burdick? Quinton? Almost certainly not Cardiac Science. We know this. Now ask yourself – who do you represent? Who are we?
Let’s discuss the vision, and the third thing you need to have the best story: 3. You have to incorporate all the strengths of the company for it to be most compelling, and promote the vision of the company To rebrand ourselves as “The company people think of first” - If we DIDN’T do this, and we asked customers “What company do YOU think of first” for cardiology products and services, who would they reply? GE? Philips? Burdick? Quinton? Almost certainly not Cardiac Science. We know this. Now ask yourself – who do you represent? Who are we?
Let’s discuss the vision, and the third thing you need to have the best story: 3. You have to incorporate all the strengths of the company for it to be most compelling, and promote the vision of the company To rebrand ourselves as “The company people think of first” - If we DIDN’T do this, and we asked customers “What company do YOU think of first” for cardiology products and services, who would they reply? GE? Philips? Burdick? Quinton? Almost certainly not Cardiac Science. We know this. Now ask yourself – who do you represent? Who are we?
Let’s discuss the vision, and the third thing you need to have the best story: 3. You have to incorporate all the strengths of the company for it to be most compelling, and promote the vision of the company To rebrand ourselves as “The company people think of first” - If we DIDN’T do this, and we asked customers “What company do YOU think of first” for cardiology products and services, who would they reply? GE? Philips? Burdick? Quinton? Almost certainly not Cardiac Science. We know this. Now ask yourself – who do you represent? Who are we?
Let’s discuss the vision, and the third thing you need to have the best story: 3. You have to incorporate all the strengths of the company for it to be most compelling, and promote the vision of the company To rebrand ourselves as “The company people think of first” - If we DIDN’T do this, and we asked customers “What company do YOU think of first” for cardiology products and services, who would they reply? GE? Philips? Burdick? Quinton? Almost certainly not Cardiac Science. We know this. Now ask yourself – who do you represent? Who are we?
Let’s discuss the vision, and the third thing you need to have the best story: 3. You have to incorporate all the strengths of the company for it to be most compelling, and promote the vision of the company To rebrand ourselves as “The company people think of first” - If we DIDN’T do this, and we asked customers “What company do YOU think of first” for cardiology products and services, who would they reply? GE? Philips? Burdick? Quinton? Almost certainly not Cardiac Science. We know this. Now ask yourself – who do you represent? Who are we?